A Phase 3 Randomized Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma

Brief description of study

The purpose of this study is to: 1)Test the safety of the study drugs: pembrolizumab in combination with gemcitabine and cisplatin 2) See how well your body handles pembrolizumab in combination with gemcitabine and cisplatin compared to placebo (a look-alike with no active ingredients) in combination with gemcitabine and cisplatin 3) See if pembrolizumab, gemcitabine and cisplatin slows cancer growth and increases the length of life compared to placebo, gemcitabine and cisplatin.


Clinical Study Identifier: s19-01279
ClinicalTrials.gov Identifier: NCT04003636


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.